A Study on the Preference of Risperidone Dosage Forms

Recruiting

• Conditions: Autism Spectrum Disorder; Conduct Disorder; Schizophrenia; Bipolar Affective Disorder; Mental Retardation

• Registration Number: NCT06657430
• Lead Sponsor: Shanghai Mental Health Center

Brief Summary

This study aimed to understand patients' needs and preferences for antipsychotic dosage forms.

Detailed Description

This study aims to understand patients' needs and preferences for antipsychotic dosage forms and to clarify the clinical value of patch-form antipsychotics.

Study Timeline

• Status Verified: 2024-09
• Study Start: 2024-09-19
• Study First Submitted: 2024-10-21
• Study First Submitted QC: 2024-10-23
• Last Update Submitted: 2024-10-23
• Study First Posted: 2024-10-24
• Last Update Posted: 2024-10-24
• Primary Completion: 2025-02-28
• Study Completion: 2025-02-28

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 1000

Inclusion Criteria

• Patients with schizophrenia, bipolar disorder, autism spectrum disorder, mental retardation or their primary caregivers who voluntarily participate in the study.

Exclusion Criteria

• Have difficulty reading and understanding Chinese or refuse to participate in the study.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Proportion of patients (and their caregivers) who prefer risperidone patch-form medicine	"through study completion, an average of 6 months	The proportion of patients (and their caregivers) who preferred risperidone patch among the respondents in this study

Secondary Outcome Measures

Name	Time	Method
Factors related to patients' preference for risperidone patch-form medicines	through study completion, an average of 6 months	Patients' evaluation of the importance of each advantage of risperidone patch in a self-made questionnaire (5-point Likert scale score)

Trial Locations

Locations (1)

Shanghai Mental Health Center; 🇨🇳 Shanghai, Shanghai, China